DIRETRIZES CLÍNICAS EASL-EASD-EASO PARA O MANEJO DA DOENÇA HEPÁTICA ESTEATÓTICA ASSOCIADA À DISFUNÇÃO METABÓLICA (MASLD): UMA REVISÃO NARRATIVA

ABSTRACT Non-Alcoholic Fatty Liver Disease (NAFLD) has been increasingly prevalent globally, posing a significant social and economic impact. Recently, NAFLD and non-alcoholic steatohepatitis were reclassified as Metabolic Dysfunction-associated Fatty Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatohepatitis (MASH), conditions arising from an imbalance between metabolic stress and inflammation. As MASLD progresses, treatment efficacy declines, potentially requiring liver transplantation. Early detection and intervention, particularly with lifestyle changes, are crucial to control and prevent disease progression. In this context, the present study consisted of a narrative review aimed at examining and analyzing the clinical guidelines of the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) in managing MASLD. These guidelines provide a comprehensive approach to the diagnosis and treatment of MASLD, focusing on early detection, liver fibrosis assessment, and management of comorbidities. They emphasize the importance of a multidisciplinary approach, with therapeutic strategies involving lifestyle modifications, pharmacological treatments such as resmetirom and metabolic agents that show promising results, particularly in more advanced stages. The combination of pharmacological therapies and lifestyle changes is crucial to prevent progression to cirrhosis and the need for liver transplantation, optimizing MASLD management and improving patient quality of life. Keywords: Fatty liver disease. Metabolic dysfunction. Clinical management. Lifestyle.